“Lenacapavir could face competition from another
Post# of 148183
(Total Views: 731)
Posted On: 08/22/2022 4:07:29 PM
“Lenacapavir could face competition from another investigational treatment, leronlimab, currently being developed by CytoDyn (OTCMKTS: CYDY). Also in the mix is ViiV Healthcare’s cabotegravir, an integrase inhibitor. Cabotegravir-based options are projected to generate the bulk of sales in the injectables segment, says GlobalData.“
https://www.thepharmaletter.com/article/gilea...g-sunlenca
https://www.thepharmaletter.com/article/gilea...g-sunlenca
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼